Since sEH is highly expressed in different regions of the brain, research on neurological conditions such as epilepsy, ischemic stroke, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury suggests that sEH inhibition can increase the levels of EETs and other EpFAs that have protective effects. Here, EPHX2 is linked to early-onset autosomal dominant Alzheimer disease.